Anish Patel, MD
Interventional Pain Medicine · Frederick, MDNPI 1508814849
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.6%), royalties or licence payments and speaking fees — rather than concentrated in one kind of arrangement. Aurora Spine, Inc. accounts for 77.9% of it on its own, with 56 other manufacturers making up the rest. Among interventional pain medicine clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,041 payments — averaging $298.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aurora Spine, Inc.$242K
- Nevro Corp.$33K
- Curonix LLC$7K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Interventional Pain Technologies Inc.$4K
- Medtronic$4K
- plus $17K from 51 others
Across 5 payments — averaging $59.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Saluda Medical Americas, Inc.$299
What the payments were for
- Royalty or licence$94,50730%
- Consulting fees$157,43251%
- Speaking & faculty fees$32,53710%
- Travel & lodging$1,8611%
- Food & beverage$22,9507%
- Education$1,8591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZIP$242,218
- Senza Spinal Cord Stimulation System$27,402
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$5,938
- Vyrsa V1$4,167
- Entyvio$4,016
- Omnia$3,760
- HA MINUTEMAN G3-R$1,954
- Prospera$1,288
- Prometra II$373
- INTELLIS ADAPTIVESTIM$340
- INTELLIS$315
- PROCLAIM$260
- PAINTEQ$243
- Zilretta$212
- INCEPTIV$184
- NEUROSTAR TMS THERAPY$153
- mild Device Kit$130
- Senza$126
- XEOMIN$124
- Proclaim IPG$121
How this compares
$311,144 in reported general payments places this provider in the 95th percentile of 56 interventional pain medicine providers in Maryland.
See all interventional pain medicine providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 31 | $21,458 |
| OxycontinOxycodone Hcl | 26 | $17,196 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 152 | $3,142 |
| Fentanyl | 21 | $2,732 |
| Morphine Sulfate ErMorphine Sulfate | 75 | $1,853 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 102 | $1,785 |
| Oxycodone Hcl | 128 | $1,775 |
| Gabapentin | 124 | $1,625 |
| Naloxone Hcl | 13 | $1,521 |
| Diclofenac Sodium | 20 | $877 |
| Tizanidine Hcl | 76 | $674 |
| Pregabalin | 54 | $554 |
| Methocarbamol | 28 | $498 |
| Tramadol Hcl | 63 | $451 |
| Cyclobenzaprine Hcl | 37 | $394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $1,395 | $21,45831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 56 interventional pain medicine providers in Maryland.
Other interventional pain medicine in Frederick
- Mark ColemanPikesville$1.3M
- Marc LoevRockville$318K
- Aneesh SinglaSalisbury$167K
- Charles SimmonsAnnapolis$62K
- Ali El-MohandesHagerstown$57K
- Michael WongBel Air$31K
- Anna IrwinBethesda$30K
- Dontese NicholsonBaltimore$27K
- Rajesh JariNottingham$26K
- Kristoffer de LaraGermantown$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.